New products and Services
Introducing eye-light®
Introducing eye-light®: A dual light therapy device for dry eye and ocular surface disease management
Essilor Instruments introduces eye-light® by Espansione Group into its product offering, providing eye care professionals with a clinically proven, dual action light therapy for the management of dry eye disease and other ocular surface conditions.
The eye-light® device combines Optimal Power Energy™ Intense Pulsed Light (OPE™ IPL) with Light Modulation™ Low-level Light Therapy (LM™ LLLT), to deliver targeted, condition-specific management for ocular surface diseases (OSD).
OPE™ IPL and LM™ LLLT jointly leveraged on eye-light® have been shown to deliver greater improvements in tear film quality and patient symptoms1 than competing IPL-only solutions, setting a new standard in light-based therapy.
Paul Cumber, instruments director at EssilorLuxottica, said: “This all-in-one approach to light therapy enables eye care practitioners to target the root cause of many ocular surface diseases, including dry eye.
“Offering this management pathway for dry eye and OSD helps expand the scope of the practice and will lead to meaningful improvements in the quality of life for patients with dry eye disease. It also helps strengthen patient trust and loyalty throughout their dry eye management journey, while elevating and differentiating the in-practice experience.”
Treatment is delivered through a course of up to four sessions, each lasting approximately 15 minutes, on average.
Whether combining Optimal Power Energy™ IPL and Light Modulation™ LLLT (PBM) or leveraging the latter alone, the treatment experience is completely painless, providing patients with a significant amelioration of both symptoms and signs of dry eye disease 2, often improving patients’ quality of life from the very first session.
The Power of Light
Combining these light therapies has been recognised in the TFOS DEWS III Management & Therapy Report3 as a key solution to manage OSD.
Beyond symptom relief, clinical studies have demonstrated superior efficacy versus long-term eye-drop therapy, improving tear stability and clinical outcomes.4 In addition, research into the light therapies have shown long-lasting results maintained for up to 18 months.5
Powerful even as a standalone therapy, LM™ LLLT alone outperforms IPL in improving tear volume and symptom reduction.6
REFERENCES
1 Castro C, Marques JH, Marta A, Baptista PM, José D, Sousa P, Menéres P, Barbosa I. Comparison of Light-Based Devices in the Treatment of Meibomian Gland Dysfunction. Cureus, 2023;15(7):e41386. doi:10.7759/cureus.41386.
2 Lim C et al. Photobiomodulation: evidence and applications in ophthalmology. Current Opinion in Ophthalmology, 2025
3 Jones L., et al. TFOS DEWS III Management and Therapy Report, American Journal of Ophthalmology, 2025
4 Meduri A., Oliverio G.W., Tedesco G., Aragona P. Combined intense pulsed light and low-level light therapy for the treatment of refractory Meibomian gland dysfunction. European Journal of Ophthalmology, 2022.
5 Leite, J., Ribeiro, B. B., Marques, J. H., Sousa, P., Pires, S., Menéres, P., & Barbosa, I. Long-term effect of intense pulsed light combined with low-level light therapy in the treatment of meibomian gland dysfunction. Revista da Sociedade Portuguesa de Oftalmologia, 2025
6 Giannaccare G., et al., Low-Level Light Therapy Versus Intense Pulsed Light for the Treatment of Meibomian Gland Dysfunction: Preliminary Results From a Prospective Randoxmized Comparative Study. Cornea, 2023; 42(2):141-144.
